Testing effectiveness (Phase 2)Study completedNCT00868608What this trial is testingStudy Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins LymphomaWho this might be right forLymphoma Pfizer 81
Testing effectiveness (Phase 2)Looking for participantsNCT07523555What this trial is testingAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesWho this might be right forRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more Beijing Biotech 96
Early research (Phase 1)Active Not RecruitingNCT04049513What this trial is testingENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)Who this might be right forLymphomas Non-Hodgkin's B-CellDiffuse Large B-cell Lymphoma (DLBCL)Primary Mediastinal B-cell Lymphoma (PMBCL)+3 more Malaghan Institute of Medical Research 30
Testing effectiveness (Phase 2)Study completedNCT05844956What this trial is testingDZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)Who this might be right forLymphoma, Non-Hodgkin Dizal Pharmaceuticals 17
Testing effectiveness (Phase 2)Study completedNCT03010358What this trial is testingEntospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaWho this might be right forAnemiaB-Cell Prolymphocytic LeukemiaGrade 1 Follicular Lymphoma+11 more Alexey Danilov, MD 24
Testing effectiveness (Phase 2)Study completedNCT03892421What this trial is testingOutpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin LymphomaWho this might be right forRelapsed Non Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma La Raza Medical Center 22
Testing effectiveness (Phase 2)Ended earlyNCT01799889What this trial is testingStudy to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic MalignanciesWho this might be right forChronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell Lymphoma+2 more Gilead Sciences 326
Early research (Phase 1)Study completedNCT02613598What this trial is testingDose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory LymphomaWho this might be right forHodgkin's LymphomaLymphoma, Non-Hodgkin University of Michigan Rogel Cancer Center 15
Not applicableEnded earlyNCT00904514What this trial is testingStudy of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical TrialWho this might be right forCancer National Institutes of Health Clinical Center (CC) 241
Testing effectiveness (Phase 2)Study completedNCT05008055What this trial is testingStudy of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaWho this might be right forRelapsed or Refractory B-cell Non-Hodgkin Lymphoma AstraZeneca 30
Testing effectiveness (Phase 2)Study completedNCT03213678What this trial is testingSamotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)Who this might be right forAdvanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma+30 more National Cancer Institute (NCI) 18
Early research (Phase 1)Study completedNCT00040950What this trial is testingBiological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaWho this might be right forLymphoma Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)WithdrawnNCT01131247What this trial is testingPH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & OfatumumabWho this might be right forChronic Lymphocytic Leukemia (CLL) Nevada Cancer Institute 37
Testing effectiveness (Phase 2)Ended earlyNCT04730349What this trial is testingBempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerWho this might be right forEpendymomaEwing SarcomaHigh-grade Glioma+7 more Bristol-Myers Squibb 15
Early research (Phase 1)Looking for participantsNCT05098613What this trial is testingPreliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL PatientsWho this might be right forNon-Hodgkin LymphomaB-cell Non-Hodgkin Lymphoma (B-NHL)Mantle Cell Lymphoma (MCL)+1 more University of Colorado, Denver 68
Testing effectiveness (Phase 2)Study completedNCT02348216What this trial is testingStudy Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin LymphomaWho this might be right forRefractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B-Cell LymphomaTransformed Follicular Lymphoma (TFL)+2 more Kite, A Gilead Company 307
Early research (Phase 1)Not Yet RecruitingNCT07068906What this trial is testingA Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaWho this might be right forB-Cell Non-Hodgkin Lymphoma Institute of Hematology & Blood Diseases Hospital, China 27
Testing effectiveness (Phase 2)Study completedNCT01693614What this trial is testingSafety and Efficacy of BKM120 in Relapsed and Refractory NHLWho this might be right forDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma Novartis Pharmaceuticals 72
Testing effectiveness (Phase 2)UnknownNCT05436223What this trial is testingHuman CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's LymphomaWho this might be right forB-cell Non-Hodgkin's Lymphoma Hrain Biotechnology Co., Ltd. 100
Early research (Phase 1)Study completedNCT00109824What this trial is testingDecitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaWho this might be right forRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Mantle Cell Lymphoma National Cancer Institute (NCI) 42